Pharmacokinetics and safety of an engineered anti-feline PD-1 chimeric antibody following repeated intravenous and subcutaneous administration in healthy cats.
Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) represent a promising strategy in feline oncology. We previously developed an anti-feline PD-1 monoclonal antibody and engineered an effector-silent variant, 1A1-2-fIgG1-M2, to abolish cytotoxic functions. However, the safety profile and plasma pharm...